CNS metastases in EGFR-mutant NSCLC are prevalent and worsen prognosis, especially with acquired progression during treatment. Amivantamab plus lazertinib shows promising CNS activity, but current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback